3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Sell
40
RAFA Quote, Financials, Valuation and Earnings
Last price:
$0.1300
Seasonality move
:
176.06%
Day range:
$0.0999 - $0.1323
52-week range:
$0.0330 - $0.1790
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
25.7K
Avg. volume:
25K
1-year change:
-10.31%
Market cap:
$11.1M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Rafarma Pharmaceuticals has -- downside to fair value with a price target of -- per share.
RAFA vs. S&P 500
-
Over the past 5 trading days, Rafarma Pharmaceuticals has overperformed the S&P 500 by 5.04% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rafarma Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rafarma Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rafarma Pharmaceuticals reported revenues of --.
Earnings Growth
-
Rafarma Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Rafarma Pharmaceuticals reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-01 | 2024-04-01 | 2024-04-01 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-04-01 | 2022-04-01 | 2023-04-01 | 2024-04-01 | ||
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-01 | 2024-04-01 | 2024-04-01 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
RAFA
Sector
Market Cap
$11.1M
--
Price % of 52-Week High
73.91%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
-10.31%
--
Beta (5-Year)
1.117
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.1368
200-day SMA
Buy
Level
$0.0877
Bollinger Bands (100)
Buy
Level
0.0887 - 0.1487
Chaikin Money Flow
Buy
Level
11.5M
20-day SMA
Sell
Level
$0.1437
Relative Strength Index (RSI14)
Sell
Level
47.1551
ADX Line
Sell
Level
14.1518
Williams %R
Neutral
Level
-58.4615
50-day SMA
Sell
Level
$0.1434
MACD (12, 26)
Sell
Level
-0.0030
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
1.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rafarma Pharmaceuticals Inc is engaged in pharmaceuticals and has several subsidiaries specializing in developing and producing medical equipment, as well as supplying equipment for hospitals and clinics from Germany, China, Slovakia, and others.
Stock Forecast FAQ
In the current month, RAFA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RAFA average analyst price target in the past 3 months is --.
-
Where Will Rafarma Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rafarma Pharmaceuticals share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Rafarma Pharmaceuticals?
Analysts are divided on their view about Rafarma Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rafarma Pharmaceuticals is a Sell and believe this share price will rise from its current level to --.
-
What Is Rafarma Pharmaceuticals's Price Target?
The price target for Rafarma Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RAFA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rafarma Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RAFA?
You can purchase shares of Rafarma Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rafarma Pharmaceuticals shares.
-
What Is The Rafarma Pharmaceuticals Share Price Today?
Rafarma Pharmaceuticals was last trading at $0.1300 per share. This represents the most recent stock quote for Rafarma Pharmaceuticals. Yesterday, Rafarma Pharmaceuticals closed at $0.1323 per share.
-
How To Buy Rafarma Pharmaceuticals Stock Online?
In order to purchase Rafarma Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 17.62% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 4.58% over the past day.
Sell
47
RGC alert for Apr 1
Regencell Bioscience Holdings [RGC] is down 4.3% over the past day.
